Gene ReportsCancer BiologyPeer-reviewed journal article
Expression of MMP-11, an estrogen-suppressed gene in MCF-7 cells, is elevated upon acquisition of tamoxifen resistance
Abstract
Matrix metalloproteinase-11 (MMP-11), also known as stromelysin-3, is a member of a large family of zinc-dependent proteinases. Known to be expressed in breast tumor stroma, the epithelium, and the associated mononuclear inflammatory cells, its expression is associated with invasion, metastasis, and poor clinical outcomes and survival rates. Despite the known effects of estrogen on extracellular matrix remodeling, and breast cancer metastasis, the role of MMP-11 therein is not understood. Here, we show that estrogen suppresses MMP-11 expression in MCF-7 breast cancer cells via a mechanism that involves binding of the estrogen receptor (ER) to an estrogen response element located in the intron-1 of MMP-11. ER knockdown alone upregulates MMP-11 expression, highlighting its crucial role in this regulatory axis. Additionally, the anti-estrogen tamoxifen (4-OHT) blocks estrogen-mediated MMP-11 suppression. However, prolonged 4-OHT exposure or 4-OHT resistance leads to increased MMP-11 expression. This suggests that MMP-11 may play a role in 4-OHT resistance, potentially leading to a more aggressive tumor phenotype. Our study underscores the importance of estrogen-ER signaling in breast cancer progression, emphasizing the need for further investigation into MMP-11s role in 4-OHT resistance and cancer metastasis.
- organism: human
- assay: bulk RNA-seq
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 1
- FWCI
- 0.59
- Field percentile
- top 36%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine Resistance
Han Wang, Zixi Yun, … Hung‐Ying Kao·bioRxiv·May 15, 2025
- In vivo CRISPR screening links NFKB1 to endocrine resistance in ER⁺ breast cancer
Cancan Lyu, Sam Hall, … Songhai Chen·Endocrine Related CancerPeer-reviewed·Sep 1, 2026
- Kinase Plasticity in Response to Vandetanib Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer
Austin A. Whitman, Rasha T. Kakati, … Philip M. Spanheimer·Molecular Cancer TherapeuticsPeer-reviewed·Jul 28, 2026
- PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and Tamoxifen in a luminal A breast cancer model
Luisa E. Schwarzmüller, Janina Müller, … Stefan Wiemann·Molecular OncologyPeer-reviewed·Jun 5, 2026
- Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
- Myosin VI orchestrates estrogen-driven gene expression in breast cancer cells.
Yukti Hari‐Gupta, Danielle Lambert, … Christopher P. Toseland·bioRxiv·Nov 13, 2025